US Patent 11981726 Antibody neutralizing human respiratory syncytial virus
Patent 11981726 was granted and assigned to Merck Sharp & Dohme Limited on May, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 15 May, 2024
Golden AI
Edits made to:
Infobox (+29 properties)
Article (+475 characters)
US Patent 11981726 Antibody neutralizing human respiratory syncytial virus
Article
Patent abstract
The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Aimin Tang0
Daniel DiStefano0
Hua-Poo Su0
Kalpit A. Vora0
Kara S. Cox0
Lan Zhang0
Zhifeng Chen0
Date of Patent
May 14, 2024
0Patent Application Number
180651720
Date Filed
December 13, 2022
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11981726 Antibody neutralizing human respiratory syncytial virus
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
